NCT02017730

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

An Open-Label Study To Evaluate The Safety and Tolerability Of A Novel LPA1 Receptor Positron Emission Tomography (PET) Ligand [11C]BMT-136088 And To Assess Receptor Occupancy In Human Lung Following Oral Administration Of BMS-986020 In Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety and tolerability of a novel positron emission tomography (PET) tracer \[11C\]BMT-136088 in healthy adult subjects for measurement of availability of Lysophosphatidic Acid (LPA1) receptors in the human lung and to use this tracer to assess LPA1 receptor occupancy using \[11C\]BMT-136088 in the human lung following oral administration of Bristol Myers Squibb (BMS)-986020.

Detailed description

End point Classification: Pharmacokinetics/Pharmacodynamics

Conditions

• Immunology

Interventions

Type	Name	Description
DRUG	BMS-986020
DRUG	[11C]BMT-136088

Timeline

• Start date: 2014-01-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2013-12-23
• Last updated: 2015-07-07

Locations

1 site across 1 country: United States